Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

New data from Novo Nordisk ... and obese patient populations, with results due in 2025. Boehringer/Zealand injectable Meanwhile, data on another potential rival in the injectable obesity category ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Medical and trade organizations, from the Obesity ... Novo Nordisk isn’t impressed. “As makers of the only real FDA-approved semaglutide medicines (Wegovy, Ozempic, and Rybelsus), patient ...